The BLA for mRNA-1083 will be resubmitted later this year once vaccine efficacy data from an ongoing phase 3 trial assessing mRNA-1010 are available. Moderna has withdrawn the Biologics License ...
The company raised its full-year 2025 revenue growth guidance to "at least 17% or revenue of at least $219 million." Gross margin guidance remains in the "range of 73% to 75%, inclusive of onetime ...
Days after a major train hijacking, the BLA targeted buses carrying Pakistani security forces. Both attacks highlight the BLA’s new strategy of combining suicide attacks with conventional guerrilla ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results